α 1-Antitrypsin deficiency-diagnosis, treatment, and control

Identification of patients

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Severe α 1-antitrypsin (AAT) deficiency is a relatively common inherited condition in populations of Northern European heritage. Current estimates of the prevalence of the PiZ phenotype range between 1/3500 and 1/1670 in the United States. Clues to the whereabouts of the undiagnosed individuals with severe hereditary AAT deficiency can come from the existing information about the natural history and clinical course of disease. In the PiZ smoker, dyspnea develops soon after age 30 years or at least before age 40, and death from emphysema is likely by age 50. The PiZ nonsmoker has a prognosis only marginally worse than that of the susceptible smoker without AAT deficiency. Dyspnea often does not appear until after age 50 years, and clinically significant emphysema not usually until after age 60. All infants presenting with liver disease in the neonatal period should be tested for the deficiency. In adults, clinically significant dyspnea in the 30s and 40s, in association with abnormal lung function, should raise the suspicion of AAT deficiency. In nonsmokers, dyspnea at any age justifies further investigation. A serum AAT level below 80 mg/dl (11 μM) is considered abnormal; individuals falling in this range should be phenotyped. The formation of a Registry for severe hereditary AAT deficiency in the United States, under the auspices of the National Heart, Lung and Blood Institute of the NIH, is also described.

Original languageEnglish (US)
Pages (from-to)543-551
Number of pages9
JournalLung
Volume168
Issue number1
DOIs
StatePublished - Dec 1990

Fingerprint

Dyspnea
Emphysema
National Heart, Lung, and Blood Institute (U.S.)
Therapeutics
Natural History
Registries
Liver Diseases
Phenotype
Lung
Serum
Population

Keywords

  • α-Antitrypsin deficiency
  • Chronic obstructive lung disease
  • Emphysema
  • Natural history

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology

Cite this

α 1-Antitrypsin deficiency-diagnosis, treatment, and control : Identification of patients. / Buist, A (Sonia).

In: Lung, Vol. 168, No. 1, 12.1990, p. 543-551.

Research output: Contribution to journalArticle

@article{912975edbb1346c88e8ba465e4b2ffb1,
title = "α 1-Antitrypsin deficiency-diagnosis, treatment, and control: Identification of patients",
abstract = "Severe α 1-antitrypsin (AAT) deficiency is a relatively common inherited condition in populations of Northern European heritage. Current estimates of the prevalence of the PiZ phenotype range between 1/3500 and 1/1670 in the United States. Clues to the whereabouts of the undiagnosed individuals with severe hereditary AAT deficiency can come from the existing information about the natural history and clinical course of disease. In the PiZ smoker, dyspnea develops soon after age 30 years or at least before age 40, and death from emphysema is likely by age 50. The PiZ nonsmoker has a prognosis only marginally worse than that of the susceptible smoker without AAT deficiency. Dyspnea often does not appear until after age 50 years, and clinically significant emphysema not usually until after age 60. All infants presenting with liver disease in the neonatal period should be tested for the deficiency. In adults, clinically significant dyspnea in the 30s and 40s, in association with abnormal lung function, should raise the suspicion of AAT deficiency. In nonsmokers, dyspnea at any age justifies further investigation. A serum AAT level below 80 mg/dl (11 μM) is considered abnormal; individuals falling in this range should be phenotyped. The formation of a Registry for severe hereditary AAT deficiency in the United States, under the auspices of the National Heart, Lung and Blood Institute of the NIH, is also described.",
keywords = "α-Antitrypsin deficiency, Chronic obstructive lung disease, Emphysema, Natural history",
author = "Buist, {A (Sonia)}",
year = "1990",
month = "12",
doi = "10.1007/BF02718177",
language = "English (US)",
volume = "168",
pages = "543--551",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - α 1-Antitrypsin deficiency-diagnosis, treatment, and control

T2 - Identification of patients

AU - Buist, A (Sonia)

PY - 1990/12

Y1 - 1990/12

N2 - Severe α 1-antitrypsin (AAT) deficiency is a relatively common inherited condition in populations of Northern European heritage. Current estimates of the prevalence of the PiZ phenotype range between 1/3500 and 1/1670 in the United States. Clues to the whereabouts of the undiagnosed individuals with severe hereditary AAT deficiency can come from the existing information about the natural history and clinical course of disease. In the PiZ smoker, dyspnea develops soon after age 30 years or at least before age 40, and death from emphysema is likely by age 50. The PiZ nonsmoker has a prognosis only marginally worse than that of the susceptible smoker without AAT deficiency. Dyspnea often does not appear until after age 50 years, and clinically significant emphysema not usually until after age 60. All infants presenting with liver disease in the neonatal period should be tested for the deficiency. In adults, clinically significant dyspnea in the 30s and 40s, in association with abnormal lung function, should raise the suspicion of AAT deficiency. In nonsmokers, dyspnea at any age justifies further investigation. A serum AAT level below 80 mg/dl (11 μM) is considered abnormal; individuals falling in this range should be phenotyped. The formation of a Registry for severe hereditary AAT deficiency in the United States, under the auspices of the National Heart, Lung and Blood Institute of the NIH, is also described.

AB - Severe α 1-antitrypsin (AAT) deficiency is a relatively common inherited condition in populations of Northern European heritage. Current estimates of the prevalence of the PiZ phenotype range between 1/3500 and 1/1670 in the United States. Clues to the whereabouts of the undiagnosed individuals with severe hereditary AAT deficiency can come from the existing information about the natural history and clinical course of disease. In the PiZ smoker, dyspnea develops soon after age 30 years or at least before age 40, and death from emphysema is likely by age 50. The PiZ nonsmoker has a prognosis only marginally worse than that of the susceptible smoker without AAT deficiency. Dyspnea often does not appear until after age 50 years, and clinically significant emphysema not usually until after age 60. All infants presenting with liver disease in the neonatal period should be tested for the deficiency. In adults, clinically significant dyspnea in the 30s and 40s, in association with abnormal lung function, should raise the suspicion of AAT deficiency. In nonsmokers, dyspnea at any age justifies further investigation. A serum AAT level below 80 mg/dl (11 μM) is considered abnormal; individuals falling in this range should be phenotyped. The formation of a Registry for severe hereditary AAT deficiency in the United States, under the auspices of the National Heart, Lung and Blood Institute of the NIH, is also described.

KW - α-Antitrypsin deficiency

KW - Chronic obstructive lung disease

KW - Emphysema

KW - Natural history

UR - http://www.scopus.com/inward/record.url?scp=0025368516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025368516&partnerID=8YFLogxK

U2 - 10.1007/BF02718177

DO - 10.1007/BF02718177

M3 - Article

VL - 168

SP - 543

EP - 551

JO - Lung

JF - Lung

SN - 0341-2040

IS - 1

ER -